Share
.webp)
.webp)
.webp)
.webp)
John Sundy
Sanofi’s Board of Directors has announced the proposal for the appointment of Clotilde Delbos, Anne-Françoise Nesmes, and John Sundy as independent Directors. Additionally, the Board will recommend the renewal of the terms of office for Rachel Duan and Lise Kingo.
Diane Souza, who serves on the Audit and Compensation Committees, and Thomas Südhof, Chairman of the Scientific Committee, will conclude their terms at the end of their second tenure. The Chairman expressed gratitude for their valuable contributions to the Board and its specialized committees.
John Sundy serves as Chief Medical Officer and Head of Research and Development at Seismic Therapeutics, a machine learning Immunology Company. He is also an Adjunct Professor of Medicine in the Division of Rheumatology and Immunology at Duke University School of Medicine. A former tenured faculty member at Duke, he transitioned to the biotech industry in 2014, holding senior positions at Gilead Sciences and Pandion Therapeutics. John Sundy is a director of Neutrolis, Inc., and the Childhood Arthritis and Rheumatology Research Alliance, and serves on the NIH Immune Tolerance Network Steering Committee. He earned a B.S. in biology from Bucknell University and an M.D./Ph.D. from Hahnemann University, specializing in immunology, with clinical training in rheumatology and allergy/immunology at Duke.
